GHDX Genomic Health, Inc. featured news, full reports, and detailed charts
Genomic Health, Inc. (GHDX) Wrap Up:
This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this Report, the words “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” and similar expressions are intended to identify forward-looking statements. These are statements that relate to future periods and include statements about our expectation that, for the foreseeable future, substantially all of our revenues will be derived from Oncotype DX, the factors we believe to be driving demand for Oncotype DX and our ability to sustain such demand; our expectation that our research and development expense levels will remain high as we seek to increase the clinical utility of Oncotype DX and develop new tests; our expectation that our general and administrative and sales and marketing expenses will increase and our anticipated uses of those funds; our expectations regarding capital expenditures; the factors that may impact o ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f14%2f0000891618-08-000165.html#FIS_BUSINESS"Genomic Health Inc. (GHDX:NASDAQ)
Snapshot of Genomic Health Inc. (GHDX)
|
OPEN
$18.98
|
PREVIOUS CLOSE
$19.04
|
|
|
DAY HIGH
$19.36
|
DAY LOW
$18.94
|
|
|
52 WEEK HIGH
04/2/09 - $27.22
|
52 WEEK LOW
07/24/09 - $15.81
|
|
|
MARKET CAP
551.9M
|
AVERAGE VOLUME 3 mo
103.0K
|
|
|
DILUTED EPS TTM
$-0.40
|
SHARES OUTSTANDING
28.6M
|
|
|
GHDX Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
GHDX Top Compensated Officers
Executives, Board Directors
Key developments for Genomic Health Inc. (GHDX)
Genomic Health Inc. reported un-audited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Total revenue increased to $39.5 million in the third quarter of 2009 compared with $28.1 million in the third quarter of 2008. Net loss decreased to $502,000 in the third quarter of 2009 from $3.0 million in the third quarter of 2008. Basic and diluted net loss per share was $0.02 in the third quarter of 2009, compared with basic and diluted net loss per share of $0.11 in the third quarter of 2008. Loss from operations was $0.533 against $3.300 of previous year period. Loss before income taxes was $0.439 compared to $3.022 for the same period last year. For the nine months ended September 30, 2009, total revenue was $110.0 million, compared with $79.3 million for the first nine months of 2008. Net loss for the nine months ended September 30, 2009 was $9.1 million, compared with $13.8 million for the first nine months of 2008. Basic and diluted net loss per share was $0.32 for the nine months ended September 30, 2009, compared with basic and diluted net loss per share of $0.49 for the first nine months of 2008. Loss from operations was $9.098 million against $14.863 million of previous year period. Loss before income taxes was $8.616 million compared to $13.755 million for the same period last year.
Genomic Health Inc., Q3 2009 Earnings Call, Nov-04 2009
Genomic Health Inc. expected to Report Fiscal Year 2009 Results on February 3, 2010. This event was calculated by Capital IQ (Created on October 28, 2009).
GHDX Competitors
| Company | Last | Change |
| Celera Group | $6.25 USD | -0.05 |
| Hi Tech Pharmacal Co Inc | $19.52 USD | +0.26 |
| Quidel Corp | $13.23 USD | -0.04 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | GHDX | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.9x |
|
| Price/Book | 8.4x |
Not meaningful
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 3.5x |
|
|
GHDX |
||
GHDX transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||